Clinical Trials Logo

Clinical Trial Summary

The efficacy of Botulinum toxin A (BoNT-A) in Asian population has not been properly studied and there is no literature available on the most efficacious dose of BoNT-A for sialorrhoea treatment. This research is aimed to find the dose of Dysport® that would be efficacious without treatment-related adverse events and the duration of effectiveness of the drug for sialorrhea treatment in Malaysian patients. The efficacy, safety, tolerability and adverse effects of three doses of Dysport®(50MU, 100MU and 200MU) are examined at 2,6,12 and 24 weeks post injection in this double-blinding, randomized trial.


Clinical Trial Description

Study Objectives:

To determine the efficacy, safety, tolerability and adverse effects of three doses of Dysport® (50MU, 100MU and 200MU) in the treatment of sialorrhoea in Asian patients with neurological disorders/diseases and to determine the most efficacious dose.

Study design:

Dose-ranging double blind pilot study.

Sample size:

At least 30 adult patients with various neurological disorders complicated with sialorrhoea including stroke, motor neurone disease, traumatic brain injury and Parkinsonism would be divided into 3 dosing groups.

Study method:

Patients who satisfy inclusion criteria and have given informed consent would be randomized into 3 equal groups given different total doses-50MU, 100MU, 200MU. The total dose will be divided equally and give to each of 4 salivary glands viz. the submandibular and parotid gland bilaterally. For example, if 200MU is to be given in total, 50MU would be given to each gland. Injections would be given via a 25G needle to each gland with ultrasound guidance for better needle placement. One site will be injected per gland.

Primary outcome measure The percentage reduction in the rate of saliva production (as measured by difference in mean weight of dental rolls per minute from baseline) for each of the groups given different doses of Dysport® at 2,6,12 and 24 weeks post injection.

Secondary outcome measure

1. Patient's subjective assessment of improvement in sialorrhoea using the Drooling Frequency and Severity Scale (Thomas-Stonell scale) at 2,6,12 and 24 weeks post-injection.

2. Duration to maximum reduction in salivation (as measured by the maximum reduction in weight of dental rolls) ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02425176
Study type Interventional
Source University of Malaya
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 2009
Completion date April 2014

See also
  Status Clinical Trial Phase
Completed NCT02610868 - Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Phase 3
Active, not recruiting NCT05164367 - Pharmacokinetics of Atropine Oral Gel Early Phase 1
Not yet recruiting NCT05097079 - Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Pediatric Subjects Phase 3
Completed NCT01994109 - Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Phase 3
Active, not recruiting NCT01489904 - Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Phase 2/Phase 3
Recruiting NCT04873115 - Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties, Phase 4
Withdrawn NCT03704168 - Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders N/A
Completed NCT01653132 - Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism Phase 2
Completed NCT00491894 - Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Phase 3
Completed NCT04197037 - Prevalence of Sialorrhea in Patients Treated With Clozapine
Completed NCT06101160 - Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
Completed NCT01191398 - Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation N/A
Completed NCT01118143 - Oral Health Literacy Tailored Communication N/A
Recruiting NCT02382198 - Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease Phase 2
Completed NCT00125203 - Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3
Completed NCT02613494 - Clozapine-induced Hypersalivation - Feasibility Trial Phase 1/Phase 2
Not yet recruiting NCT03747536 - Ipratropium Bromide Spray as Treatment for Sialorrhea in Children Phase 2
Completed NCT01551940 - Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea Phase 2
Completed NCT00683891 - FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey N/A